TY - JOUR AU - Camarero, Jorge AU - Ruiz, Sol PY - 2012 TI - Immunotherapy in renal cell cancer: the more the merrier? JF - Translational Andrology and Urology; Vol 2, No 2 (June 16, 2013): Translational Andrology and Urology Y2 - 2012 KW - N2 - Renal cell carcinoma (RCC) is the most common primary malignancy affecting the kidney and considered a disease refractory to systemic therapy beyond cytokine therapy (the use of interferon alfa and interleukin 2 was limited when targeted therapies became available) (1). Currently, eight drugs are approved in the European Union (EU) for the treatment of advanced RCC, including IL-2, IFN-α, sorafenib, sunitinib, everolimus, temsirolimus, bevacizumab in combination with IFN-α, and pazopanib. UR - https://tau.amegroups.org/article/view/1160